TCM
CORT icon

Teza Capital Management’s Corcept Therapeutics CORT Stock Holding History

Teza Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,088
Closed -$467K – 350
2025
Q1 		$467K Sell
4,088
-122
-3% -$7.43K 0.21% 156
2024
Q4 		$212K Buy
+4,210
New +$221K 0.03% 426
2024
Q2 		– Sell
-13,060
Closed -$329K – 606
2024
Q1 		$329K Buy
13,060
+6,624
+103% +$156K 0.04% 419
2023
Q4 		$209K Sell
6,436
-1,131
-15% -$31.1K 0.04% 494
2023
Q3 		$206K Buy
+7,567
New +$219K 0.03% 526
2020
Q3 		– Sell
-35,919
Closed -$604K – 418
2020
Q2 		$604K Buy
+35,919
New +$505K 0.13% 240
2020
Q1 		– Sell
-37,143
Closed -$449K – 202
2019
Q4 		$449K Buy
+37,143
New +$517K 0.12% 305

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Teza Capital Management's CORT Position: Q2 2025 in Review

Teza Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 4,088 shares — an estimated $467K sold.

Teza Capital Management first reported a position in CORT in Q4 2019 and held it in 7 quarters. The position peaked at $604K in Q2 2020. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Teza Capital Management reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Teza Capital Management sold 4,088 Corcept Therapeutics shares in Q2 2025, an estimated $467K.
  • Teza Capital Management first reported a position in Corcept Therapeutics in Q4 2019 and held it in 7 quarters.
  • Teza Capital Management's Corcept Therapeutics position peaked at $604K in Q2 2020.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.